Raymond James & Associates Chinook Therapeutics, Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	BUY	$18.66 - $38.58 $26,198 - $54,166	1,404 Added 10.12%	15,281 $587,000
Q1 2023 Apr 14, 2023	BUY	$21.53 - $26.8 $732 - $911	34 Added 0.25%	13,877 $321,000
Q4 2022 Feb 08, 2023	SELL	$18.63 - $27.35 $3,986 - $5,852	-214 Reduced 1.52%	13,843 $362,000
Q3 2022 Oct 25, 2022	BUY	$17.51 - $23.37 $5,935 - $7,922	339 Added 2.47%	14,057 $276,000
Q2 2022 Aug 12, 2022	BUY	$12.59 - $18.8 $172,709 - $257,898	13,718 New	13,718 $240,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.